Clinical translation in the treatment of hepatocellular carcinoma following the introduction of contrast-enhanced ultrasonography with Sonazoid

Hiraoka,Atsushi; Ichiryu,Misa; Tazuya,Nayu; Ochi,Hironori; Tanabe,Atsushi; Nakahara,Hiromasa; Hidaka,Satoshi; Uehara,Takahide; Ichikawa,Soichi; Hasebe,Aki; Miyamoto,Yasunao; Ninomiya,Tomoyuki; Hirooka,Masashi; Abe,Masanori; Hiasa,Yoichi; Matsuura,Bunzo; Onji,Morikazu; Michitaka,Kojiro

doi:10.3892/ol_00000010

Clinical translation in the treatment of hepatocellular carcinoma following the introduction of contrast-enhanced ultrasonography with Sonazoid

Authors:
- Atsushi Hiraoka
- Misa Ichiryu
- Nayu Tazuya
- Hironori Ochi
- Atsushi Tanabe
- Hiromasa Nakahara
- Satoshi Hidaka
- Takahide Uehara
- Soichi Ichikawa
- Aki Hasebe
- Yasunao Miyamoto
- Tomoyuki Ninomiya
- Masashi Hirooka
- Masanori Abe
- Yoichi Hiasa
- Bunzo Matsuura
- Morikazu Onji
- Kojiro Michitaka
View Affiliations

Affiliations: Ehime Prefectural Central Hospital, Ehime 790-0024, Japan. hirage@m.ehime-u.ac.jp
Published online on: January 1, 2010 https://doi.org/10.3892/ol_00000010
Pages: 57-61

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Some hepatocellular carcinoma (HCC) nodules are detectable with dynamic computed tomography, but not by conventional B-mode ultrasonography (US). Contrast-enhanced US (CEUS) with Sonazoid, a new injectable contrast agent, has been used in Japan since January 2007. The primary advantage of this agent is the ability to maintain observations continuously in the Kupffer phase. We assessed the clinical role of CEUS with Sonazoid for radiofrequency ablation (RFA). From January 2005 to December 2008, 1142 patients were treated with surgical resection, RFA, percutaneous ethanol injection or transcatheter arterial chemoembolization, following the exclusion of those patients treated with chemotherapy or supportive care. The patients included in the study were divided into the pre-CEUS (n=451, 2005 and 2006) and post-CEUS (n=691, 2007 and 2008) groups. Clinical background (e.g., etiology, Child-Pugh classification, tumor node metastasis stage, percentage of patients matched with Milan criteria and selected therapies) was compared between the two groups. In addition, na?ve cases were compared between the groups. There were 130 naïve HCC cases in the pre-CEUS group and 171 in the post-CEUS group. Although there were no significant differences for clinical background, the percentage of RFA cases increased from 21 (n=95) to 32% (n=219) and from 32 (n=41) to 52% (n=89) for total and naïve subjects, respectively, after CEUS was introduced (P<0.01). In naïve cases treated with RFA, tumor numbers in the post-CEUS group were larger than those of the pre-CEUS group (1.15±0.48 vs. 1.40±0.67; P<0.01). CEUS with Sonazoid, therefore, makes it possible to perform RFA in a considerable number of HCC cases that would otherwise be invisible by conventional B-mode US.

View Figures

View References

1	Rossi S, Di Stasi M, Buscarini E, et al: Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. Am J Roentgenol. 167:759–768. 1996. View Article : Google Scholar : PubMed/NCBI
2	Tateishi R, Shiina S, Teratani T, et al: Percutaneous radio-frequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer. 103:1201–1209. 2005.PubMed/NCBI
3	Shiina S, Teratani T, Obi S, Hamamura K, Koike Y and Omata M: Nonsurgical treatment of hepatocellular carcinoma: from percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation. Oncology. 62:64–68. 2002. View Article : Google Scholar
4	Ng KK and Poon RT: Role of radiofrequency ablation for liver malignancies. Surg Practice. 9:94–103. 2005. View Article : Google Scholar
5	Hiraoka A, Horiike N, Yamashita Y, et al: Efficacy of radio-frequency ablation therapy compared to surgical resection in 164 patients in Japan with single hepatocellular carcinoma smaller than 3 cm, along with report of complications. Hepatogastroenterology. 55:2171–2174. 2008.
6	Kindberg GM, Tolleshaug H, Roos N, et al: Hepatic clearance of Sonazoid perfluorobutane microbubbles by Kupffer cells does not reduce the ability of liver to phagocytose or degrade albumin microspheres. Cell Tissue Res. 312:49–54. 2003.
7	Hatanaka K, Kudo M, Minami Y and Maekawa K: Sonazoid-enhanced ultrasonography for diagnosis of hepatic malignancies: comparison with contrast-enhanced CT. Oncology. 75:42–47. 2008. View Article : Google Scholar : PubMed/NCBI
8	Kan M, Horiike N, Hiraoka A, et al: Comparison diagnostic efficacy of contrast enhances ultrasonography with Perflubutane and dynamic computed tomography in patients with liver tumors smaller than 2 cm. Hepatol Int. 2:A2552008.
9	Numata K, Morimoto M, Ogura M, et al: Ablation therapy guided by contrast-enhanced sonography with Sonazoid for hepatocellular carcinoma lesions not detected by conventional sonography. J Ultrasound Med. 27:395–406. 2008.
10	Shiina S, Teratani T, Obi S, et al: Percutaneous ethanol injection therapy for liver tumors. Eur J Ultrasound. 13:95–106. 2001. View Article : Google Scholar : PubMed/NCBI
11	Takayasu K, Arii S, Ikai I, et al: Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology. 131:461–469. 2006. View Article : Google Scholar : PubMed/NCBI
12	Hiraoka A, Kumagi T, Hirooka M, et al: Prognosis following transcatheter arterial embolization for 121 patients with unresectable hepatocellular carcinoma with or without a history of treatment. World J Gastroenterol. 12:2075–2079. 2006.
13	Makuuchi M and Kokudo N: Clinical practice guidelines for hepatocelluar carcinoma: the first evidence based guidelines from Japan. World J Gastroenterol. 12:828–829. 2006.PubMed/NCBI
14	Bruix J and Sherman M: Management of hepatocellular carcinoma. Hepatology. 42:1208–1236. 2005. View Article : Google Scholar
15	Pugh RN, Murray-Lyon IM, Dawson JL, et al: Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 60:646–649. 1973. View Article : Google Scholar : PubMed/NCBI
16	Liver Cancer Study of Japan. The General Rules for the Clinical and Pathological Study of Primary Liver Cancer. 4th edition. Kanehara; Tokyo: pp. 192000
17	Kudo M, Chung H, Haji S, et al: Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with CLIP score. Hepatology. 40:1396–1405. 2004. View Article : Google Scholar : PubMed/NCBI
18	Mazzafero V, Regalia E, Doci R, et al: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 334:693–699. 1996. View Article : Google Scholar : PubMed/NCBI
19	Watanabe R, Matsumura M, Chen CJ, et al: Characterization of tumor imaging with microbubble-based ultrasound contrast agent, Sonazoid, in rabbit liver. Biol Pharm Bull. 28:972–977. 2005. View Article : Google Scholar : PubMed/NCBI
20	Watanabe R, Matsumura M, Munemasa T, et al: Mechanism of hepatic parenchyma-specific contrast of microbubble-based contrast agent for ultrasonography: microscopic studies in rat liver. Invest Radiol. 42:643–651. 2007. View Article : Google Scholar
21	Kindberg GM, Tolleshaug H, Roos N, et al: Hepatic clearance of Sonazoid perfluorobutane microbubbles by Kupffer cells does not reduce the ability of liver to phagocytose or degrade albumin microspheres. Cell Tissue Res. 312:49–54. 2003.
22	Uehara T, Hirooka M, Ishida K, et al: Percutaneous ultrasound-guided radiofrequency ablation of hepatocellular carcinoma with artificially induced pleural effusion and ascites. J Gastroenterol. 42:306–311. 2007. View Article : Google Scholar
23	Minami Y, Kudo M, Kawasaki T, et al: Percutaneous radiofrequency ablation guided by contrast-enhanced harmonic sonography with artificial pleural effusion for hepatocellular carcinoma in the hepatic dome. Am J Roentgenol. 182:1224–1226. 2004. View Article : Google Scholar
24	Wang JH, Lu SN, Hung CH, et al: Small hepatic nodules (≤2 cm) in cirrhosis patients: characterization with contrast-enhanced ultrasonography. Liver Int. 26:928–934. 2006.
25	Livraghi T, Meloni F, Di Stasi M, et al: Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology. 47:82–89. 2008. View Article : Google Scholar